Browse by Audience
Skip to content
Papers of the Week
Perampanel as First Adjunctive Treatment in Patients with Focal-Onset Seizures in the FAME Study: Analyses of Dose-Related Efficacy, Safety and Clinical Factors Associated with Response.
Abstract
Perampanel is approved for the adjunctive treatment of focal-onset seizures (FOS) with or without secondary generalized seizures. The FAME (Fycompa as first Add-on to Monotherapy in patients with Epilepsy; NCT02726074) study evaluated the efficacy and safety of perampanel added to monotherapy in patients with FOS with or without secondary generalized seizures (SGS). analyses of the FAME study assessed potential predictors of response and an in-depth evaluation of the safety and efficacy of perampanel.